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Abstract 
Objectives 
Poor adherence to immunosuppressive treatment is common in patients with systemic lupus 
erythematosus and may identify those with lupus nephritis (LN) who have a poorer 
prognosis. Non-adherence has also been reported to be a potential adverse outcome 
predictor in renal transplantation (rTp). We investigated whether non-adherence is 
associated with increased rTp graft rejection and/or failure in patients with LN. 
Methods 
Patients with LN undergoing rTp in two major London hospitals were retrospectively 
included. Medical and electronic records were reviewed for documented concerns of non-
adherence as well as laboratory biochemical drug levels. The role of non-adherence and 
other potential predictors of graft rejection/failure including demographics, comorbidities, age 
at systemic lupus erythematosus and LN diagnosis, type of LN, time on dialysis prior to rTp 
and medication use were investigated using logistic regression. 
Results 
Out of 361 patients with LN, 40 had rTp. During a median follow-up of 8.7 years, 17/40 
(42.5%) of these patients had evidence of non-adherence. A total of 12 (30.0%) patients 
experienced graft rejection or failure or both. In the adherent group 2/23 (8.7%) had graft 
rejection, whilst in the non-adherent this rose to 5/17 (29.4%, p = 0.11). Graft failure was 
seen in 5/23 (21.7%) patients from the adherent group and 4/17 (23.5%) in the non-adherent 
group (p = 0.89). Non-adherent patients had a trend towards increased graft rejection, 
hazard ratio 4.38, 95% confidence interval = 0.73–26.12, p = 0.11. Patients who spent more 
time on dialysis prior to rTp were more likely to be adherent to medication, p = 0.01. 
Conclusion 
Poor adherence to immunosuppressive therapy is common and has been shown to 
associate with a trend towards increased graft failure in patients with LN requiring rTp. This 
is the first paper to report that shorter periods on dialysis prior to transplantation might lead 
to increased non-adherence in lupus patients. 
 
Introduction 
According to the World Health Organization medication adherence is “the extent 
to which a person's behaviour (taking medications, following a recommended diet 
and/or executing lifestyle changes) corresponds with the agreed 
recommendations of a health care provider”.1 We and others have shown that 
adherence to medication is variable in patients with systemic lupus erythematosus 
(SLE), with poor adherence often affecting more than 50% of the patients; this 
might potentially be associated with worse overall prognosis.2–4 
Renal transplantation (rTp) for patients with lupus nephritis (LN) is an increasingly 
utilized therapy for end stage renal disease.5,6 However, the sparsity of suitable 
donors and frequent allosensitization of lupus patients due to receipt of blood 
products and prior pregnancies mean that most patients spend significant time on 
dialysis before transplantation. Poor adherence to immunosuppressive therapy 
has been shown to be associated with increased graft failure in renal transplant 
patients. Up to 16% of graft losses are attributed, in part, to poor adherence.7,8 
It is recognized that in patients with rTp non-adherence can lead to acute and 
chronic rejection, reduced renal function potentially necessitating return to dialysis 
and even death.9 Returning to dialysis after a failed renal transplant is associated 
with a 78% mortality risk compared to patients on the transplant waiting list 
receiving dialysis.10 However, despite the available evidence linking non-
adherence to adverse outcomes in patients with transplantation, little is known 
regarding adherence in patients with LN following rTp and whether less adherent 
patients have worse outcomes. 
In this study we investigated potential factors leading to non-adherence in patients 
with SLE who underwent rTp for LN and whether evidence of non-adherence 
associates with increased renal graft rejection, defined as an acute deterioration 
in the graft function associated with specific histopathological changes in the graft; 
or with failure, defined as the need for dialysis or re-transplantation. 
Methods 
All patients with diagnoses of both SLE and renal failure leading to rTp from two 
major London hospitals (University College London Hospital and Royal Free 
Hospital) since 1975 were retrospectively identified and included in this study 
analyzing prospectively captured data. All patients fulfilled ≥ 4 of the 1982 revised 
classification criteria for SLE of the American College of Rheumatology11 and we 
used the International Society of Nephrology/Renal Pathology Society 2003 
classification system to define the histological class of LN.12 Patients receiving a 
transplant prior to 1982 were retrospectively shown to fulfil the 1982 criteria. 
We retrospectively reviewed hospital electronic and paper records and 
correspondence with family practitioners and with other hospital physicians to 
identify any documented concerns about non-adherence to prescribed 
immunosuppressive treatment. Such concerns would usually be documented if 
the patients volunteered that they were not adherent to the medication 
themselves, or the information came from family members or the patients 
admitted to this following direct questioning. Furthermore, in the United Kingdom 
repeat prescriptions are facilitated by the general practitioner looking after the 
patients in the community. Therefore, if the patients do not renew their 
prescriptions in the community, the general practitioner or the pharmacist will 
quickly become aware of this and will bring this to the attention of the clinical team 
for further evaluation. A recent article revealed that although patient reporting 
could detect even relatively infrequently missed tablets, drug monitoring could 
also identify severe non-adherence.3 Thus, we also reviewed the trough blood 
levels recorded for patients on tacrolimus or ciclosporin and mycophenolate 
mofetil to help ascertain evidence of non-adherence. As there is no standard 
biochemical definition of non-adherence for patients with a renal transplant, we 
took a realistic and pragmatic approach of defining non-adherence as evidence of 
sub-therapeutic drug levels in routine measuring in >50% of the readings taken, at 
least 6 months after the rTp to avoid levels taken during the initial introduction of 
the medication and individual dose adjusting. We used the percentage of sub-
therapeutic trough levels of immunosuppressant medication as a surrogate 
marker of poor adherence rather than trough level variability, as the former has 
been reported to be more strongly associated with graft rejection after kidney 
transplantation.7 Finally, we examined potential associations with poor adherence 
including sex, ethnicity, age at SLE diagnosis, age at LN diagnosis, age when 
dialysis was started, duration of SLE diagnosis to LN, histological type of LN, time 
on dialysis prior to transplantation, and other existing conditions such as diabetes 
mellitus, hypertension, dyslipidaemia and prior cardiovascular disease. The 
primary endpoint was renal graft rejection (defined as acute deterioration in graft 
function with rejection confirmed histopathologically) occurring > 12 months from 
the transplantation. Secondary endpoints included renal graft failure (defined as a 
need for dialysis or re-transplantation) and a composite endpoint of graft rejection 
and/or failure > 12 months from the transplant. As such, if graft failure was 
identified the patients were censored for the purposes of the secondary outcomes, 
but continued to be monitored for the primary endpoint of renal graft rejection in 
the second transplant. The study was a retrospective review of a long-term 
observational registry and, in effect, an audit for which University College London 
does not require formal ethical permission. 
Statistical analysis 
Categorical variables are presented as number and percentage whilst continuous 
variables are presented as mean and standard deviation (if normally distributed) 
or otherwise median and interquartile range. Comparisons between groups were 
performed using Student's t-test for normally distributed data or the Mann–
Whitney U test for other data or Fisher's exact test. Logistic regression was used 
to investigate the potential association between non-adherence and renal graft 
rejection or failure. A p < 0.05 was considered significant. IBM SPSS version 25 
(IBM Corp., Armonk, NY, USA) was used for statistical analyses. 
Results 
Three hundred and sixty-one patients with SLE were identified with LN, the vast 
majority biopsy confirmed (>90%), of whom 40 had rTp for LN. A total of 17/40 
(42.5%) patients were identified to be non-adherent to prescribed treatment for LN 
(Figure 1). 
 Figure 1 Flow diagram indicating the study population included in this cohort. 
SLE: systemic lupus erythematosus. 
As shown in Table 1, the only significant difference between the adherent and 
non-adherent groups was the amount of time spent on dialysis with the adherent 
group spending 33 (27–79) months on dialysis versus the non-adherent group 
spending 17 (10–24) months on dialysis, p = 0.01. There were no other significant 
differences in adherent and non-adherent patients. In particular, in this cohort 
there was no difference between the groups with regards to the age at SLE 
diagnosis or rTp, gender, ethnicity, diagnosis duration, medication prescribed or 
donor source. In addition, there were no significant differences in other 
comorbidities between the two groups as shown in Table 1 (all values p > 0.05). 
Furthermore, there was no difference in adherence versus non-adherence 
patterns in patients who had received rTp prior to the year 2000 or after this time. 
Moreover, there was no difference in the group that had ever received 
azathioprine or ciclosporin, compared to the group that had never received either 
of these medications in terms of adherence (all values p > 0.05). This would 
support the assumption that even if immunotherapeutic regimes were modified 
during the period of the study, this was unlikely to affect the pattern of 
adherence/non-adherence. 
 
 Table 1 Patient demographic comparison between 
adherent and non-adherent groups 
 
 




One patient received three rTps in total and had a rejection on the initial 
transplant. Two more patients received two rTps each. One had rejection on the 
initial graft whilst the second one did not have evidence of rejection either on the 
first or second graft. 
Recording a concern about non-adherence, either following medical consultation 
or biochemically, supported a trend to increased graft rejection. During a median 
follow-up of 8.7 years, 17/40 (42.5%) of patients had evidence of non-adherence 
(Table 1). A total of 12 (30.0%) patients experienced graft rejection or failure or 
both. From the adherent group 2/23 (8.7%) had graft rejection whilst from the non-
adherent group this was 5/17 (29.4%, p = 0.11). Graft failure was seen in 5/23 
(21.7%) patients from the adherent group and 4/17 (23.5%) in the non-adherent 
group (p = 0.89). Using logistic regression, non-adherent patients had a trend 
towards increased renal graft rejection (hazard ratio 4.38, 95% confidence interval 
0.73–26.12, p = 0.11). There were no significant predictors for graft rejection or 
failure or the composite endpoint of either of them as shown in Table 2. However, 
presence of class IV LN on pre-transplant histology had a trend towards a greater 
risk of graft rejection/failure (p = 0.06). 
 
Table 2 Logistic regression hazard modelling 
investigating non-adherence and other potential 
predictors and graft failure 
 
Table 2 Logistic regression hazard modelling investigating non-adherence and other 
potential predictors and graft failure 
 
 
Interestingly, a longer time on dialysis prior to the transplantation was associated 
with decreased non-adherence. For every additional month on dialysis non-
adherence was reduced by hazard ratio 0.96, 95% confidence interval 0.93–
0.99, p = 0.02. A receiver operating characteristic curve (Figure 2) identified that 
spending more than 25 months on dialysis was more likely to lead to better 
adherence with sensitivity 0.77, specificity 0.82 and good discrimination with area 
under the curve=0.76, supporting the idea that patients who spend more time on 
dialysis are more likely to be more adherent, and thus those with less time spent 
on dialysis prior to transplantation are more likely to become non-adherent. 
 
Figure 2 Receiver operating characteristic (ROC) curve indicating that dialysis time 
of more than 25 months prior to renal transplantation was associated with improved 




In this study we considered the role of adherence to immunosuppressive 
treatment in patients with LN requiring rTp. We documented, for the first time, 
adherence patterns specifically for this cohort of patients and also investigated 
whether non-adherence was associated with an increased risk of graft rejection 
and/or failure. Our results confirmed that more than 2/5 of our patients with LN, 
even after rTp, were considered to be non-adherent, either based on medical 
record evidence or based biochemically on drug level testing. 
What is particularly noteworthy is that once a concern about non-adherence was 
documented either in the medical notes or as evidenced with biochemical assays, 
there was a trend to more than a four-fold higher risk of graft rejection, indicating 
that poor adherence could have potentially significant adverse effects. 
As this was an observational retrospective study, it was not possible to investigate 
causality leading to non-adherence. However, our results raise the strong 
possibility that patients who spend more time on dialysis are, in fact, more 
adherent to medication following transplantation. This is an important novel 
finding, as it may suggest that the time spent on dialysis has an indirect effect in 
encouraging better adherence post-transplant, perhaps because patients are 
more motivated to avoid returning to dialysis. With an increasing number of pre-
emptive transplantation6,13 it is possible that non-adherence could also increase, 
and therefore the clinicians and other health care professionals should be aware 
and ever vigilant in recognizing this. We have recently shown that increasing time 
on dialysis prior to rTp adversely affects prognosis specifically in lupus 
patients,14 supporting previous literature in patients with renal disease of mixed 
aetiology receiving rTp,15 and therefore minimizing the time on dialysis should 
remain the aim. However, particular attention should be paid to the patients who 
spent little or no time on dialysis to ensure that non-adherence does not 
compromise the beneficial effects of early transplantation. 
Limitations 
Although we included patients from two large hospitals in London over a four-
decade period, we were only able to identify 40 eligible transplanted patients from 
an original cohort of 361 patients. This number, although modest, is in line with or 
larger than other similar published studies of LN.16,17 Our study was retrospective; 
however, we endeavoured to avoid any bias by only considering strong pre-
defined surrogates for non-adherence, such as clear documentation in the notes 
about poor adherence, or biochemical markers of non-adherence, and a well-
defined endpoint of graft rejection and failure. 
Moreover, we had a mixture of Caucasian, Afro-Caribbean and Asian patients and 
therefore our study results cannot be extrapolated to other populations. In view of 
this and also the relatively modest numbers in this study, we might have been 
underpowered to detect small but significant differences specific to individual 
ethnicity. As we focused our research only in the LN renal transplant patients, we 
are not able to comment about whether adherence in this cohort is higher or lower 
than the patients remaining on dialysis. In addition, the retrospective nature of the 
study did not allow us to screen accurately for depression, a factor known to be 
associated with non-adherence in the general lupus population.18 Finally, despite 
one of the longest recorded follow-up periods exceeding 422 patient-years, we 
only had 12 patients with graft rejection or failure, which may have impacted on 
identifying smaller potential associations with the other variables included in this 
study. 
Conclusion 
In conclusion, this study with a notably long-term follow-up has shown that poor 
adherence persists in patients with LN even after rTp. It further shows that poor 
adherence may be associated with worse renal graft rejection and that shorter 
periods on dialysis prior to transplantation might lead to increased non-adherence. 
This is the first study to support such a conclusion. Further research needs to be 
undertaken collaboratively in multiple centres to identify the true adverse role of 
non-adherence in patients with renal transplant due to LN. Such studies can also 
investigate further the factors leading to poor adherence in this cohort of patients. 
Identifying patients at risk of non-adherence utilizing a combination of methods 
based on such factors is a key step. More importantly, patients at risk of or with 
documented concerns about adherence should be closely followed up with regular 
biochemical testing, and a purposeful discussion about the likely consequences of 
non-adherence in the outpatient clinics may be necessary. Finally, enhanced 
education sessions highlighting the importance of immunosuppressive therapy 
adherence could be considered for all the lupus patients following rTp but also 
importantly in anticipation of rTp. 
Key messages 
 Non-adherence to immunosuppressive medication following renal 
transplantation in patients with lupus nephritis is common 
 Non-adherence might lead to increased graft rejection following renal 
transplantation for lupus nephritis 
 Longer periods on dialysis prior to renal transplantation are associated with 
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